List of Excipients in Branded Drug JUNEL

Generic Drugs Containing JUNEL

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	norethindrone acetate and ethinyl estradiol	0555-9025	ACACIA
Teva Pharmaceuticals USA Inc	norethindrone acetate and ethinyl estradiol	0555-9025	D&C YELLOW NO. 10 ALUMINUM LAKE
Teva Pharmaceuticals USA Inc	norethindrone acetate and ethinyl estradiol	0555-9025	LACTOSE MONOHYDRATE
Teva Pharmaceuticals USA Inc	norethindrone acetate and ethinyl estradiol	0555-9025	MAGNESIUM STEARATE
Teva Pharmaceuticals USA Inc	norethindrone acetate and ethinyl estradiol	0555-9025	MALTODEXTRIN
Teva Pharmaceuticals USA Inc	norethindrone acetate and ethinyl estradiol	0555-9025	STARCH, CORN

What are the Most Frequently-Used Excipients in JUNEL?

# Of NDCs	Excipient
3	ACACIA
3	D&C YELLOW NO. 10 ALUMINUM LAKE
3	LACTOSE MONOHYDRATE
3	MAGNESIUM STEARATE
3	MALTODEXTRIN
3	STARCH, CORN

Last updated: August 3, 2026

ecutive summary: Junel is a mature combined oral contraceptive franchise based on norethindrone acetate and ethinyl estradiol. Its commercial value is driven less by compound patents than by formulation consistency, manufacturing reliability, pharmacy-channel access, packaging, patient adherence, and cost control. The core excipient opportunity is to preserve bioequivalence while improving tablet robustness, swallowability, gastrointestinal tolerability, color differentiation, and supply-chain resilience. The strongest near-term opportunities are authorized-generic supply, private-label versions, low-cost reformulation, lactose-reduced or lactose-free alternatives, and packaging designed to reduce missed doses.

Junel Excipient Strategy and Commercial Opportunities

What is Junel and which formulations are commercially relevant?

Junel is a family of oral contraceptive products containing norethindrone acetate and ethinyl estradiol. The primary strengths are:

Product	Hormonal tablets	Ferrous fumarate tablets	Typical regimen
Junel 1/20	Norethindrone acetate 1 mg; ethinyl estradiol 20 mcg	None	21 active tablets, followed by a hormone-free interval
Junel Fe 1/20	Norethindrone acetate 1 mg; ethinyl estradiol 20 mcg	75 mg ferrous fumarate per tablet	21 active tablets plus 7 iron-containing tablets
Junel 1.5/30	Norethindrone acetate 1.5 mg; ethinyl estradiol 30 mcg	None	21 active tablets, followed by a hormone-free interval
Junel Fe 1.5/30	Norethindrone acetate 1.5 mg; ethinyl estradiol 30 mcg	75 mg ferrous fumarate per tablet	21 active tablets plus 7 iron-containing tablets

Junel products are prescription combined hormonal contraceptives. The active tablets contain a low dose of ethinyl estradiol with norethindrone acetate. The Fe products use ferrous fumarate in the non-hormonal tablets to maintain a daily tablet-taking routine. The iron tablets do not provide contraceptive activity. Product labeling identifies the inactive ingredients and tablet components used in the marketed formulations (DailyMed, 2024a; DailyMed, 2024b).

What excipients are used in Junel products?

The exact excipient composition varies by strength, tablet color, supplier, and manufacturing presentation. Public labeling identifies common tablet and coating materials, including lactose monohydrate, magnesium stearate, pregelatinized starch, povidone, talc, hypromellose, titanium dioxide, and polyethylene glycol. The ferrous fumarate tablets use a separate excipient system from the hormonal tablets.

The functional roles are more important than the ingredient names:

Excipient class	Likely function in Junel-type tablets	Strategic relevance
Lactose monohydrate	Diluent and compressibility aid	Low-cost, established, but creates a lactose-intolerance and label-positioning issue
Pregelatinized starch	Binder and disintegrant	Supports tablet strength and rapid breakup
Povidone	Binder	Controls granule formation and content uniformity
Magnesium stearate	Lubricant	Reduces tooling friction; excessive levels can slow dissolution
Talc	Glidant or anti-adherent	Supports powder flow and tablet manufacture
Hypromellose	Film-coating polymer	Improves appearance, handling, and moisture protection
Titanium dioxide	Opacifier and colorant	Provides tablet color and visual differentiation
Polyethylene glycol	Coating plasticizer	Improves film flexibility
Ferrous fumarate	Iron source in Fe tablets	Differentiates the regimen and supports a seven-tablet reminder sequence

For low-dose hormonal tablets, content uniformity is a primary technical issue. The active ingredients are present at microgram-to-milligram quantities, so particle-size distribution, blending, segregation, and lubrication time can materially affect batch performance. Excipient selection must support uniform distribution without creating dissolution variability.

How should an excipient strategy be designed for Junel?

A practical strategy should prioritize five criteria: content uniformity, dissolution, tablet robustness, patient acceptability, and manufacturing cost.

1. Preserve low-dose uniformity

Norethindrone acetate and ethinyl estradiol require a controlled blending process. Direct compression can reduce processing steps, but it may increase segregation risk when active ingredients and excipients have different particle sizes or densities. Wet granulation can improve blend uniformity and flow but adds water, drying, process time, and stability controls.

A robust development program should evaluate:

• Particle-size distribution of both active ingredients
• Ordered mixing or carrier-based dilution
• Blend segregation during transfer and hopper residence
• Lubrication time and magnesium stearate concentration
• Tablet-to-tablet weight and assay variability
• Content uniformity across the beginning, middle, and end of compression
• Dissolution under multiple agitation and pH conditions

The commercial objective is not simply a lower-cost formula. It is a formula that maintains regulatory performance after scale-up and across multiple excipient suppliers.

2. Reduce dependence on lactose where commercially justified

Lactose is a cost-effective pharmaceutical diluent, but lactose-free positioning can support selected pharmacy, telehealth, and consumer-health channels. Potential substitutes include microcrystalline cellulose, mannitol, dibasic calcium phosphate, and modified starch systems.

Each alternative has tradeoffs:

Alternative	Potential benefit	Main development issue
Microcrystalline cellulose	Strong compaction and broad supplier availability	May alter tablet density, disintegration, and powder flow
Mannitol	Good mouthfeel and lower hygroscopicity than some polyols	Higher cost and possible compression limitations
Dibasic calcium phosphate	Good flow and robust tablets	Can affect dissolution and may be unsuitable for certain formulation designs
Coprocessed excipients	Improved flow and compression	Higher cost and possible supplier concentration
Starch-based systems	Familiar regulatory profile and good disintegration	Moisture sensitivity and batch-to-batch variability

A lactose-free Junel-equivalent product would require comparative dissolution, stability, bioequivalence, and excipient safety evaluation. The commercial claim should remain precise. "Lactose-free" is a formulation attribute, not a guarantee of improved tolerability for every patient.

3. Optimize tablet size and swallowability

Junel tablets are small-dose products, so tablet size can often be reduced without compromising dose delivery. Smaller tablets may improve adherence, particularly for patients taking multiple medicines. The limitation is that the hormone tablet must remain large enough to provide reliable mechanical strength, legible identification, and consistent film coating.

Mannitol, microcrystalline cellulose, and selected coprocessed excipients can support compact tablets. However, lower tablet mass can magnify manufacturing variability. The development target should balance:

• Tablet diameter and thickness
• Breaking force
• Friability
• Disintegration time
• Coating weight gain
• Printing or embossing requirements
• Packaging resistance to abrasion and moisture

4. Improve dissolution without compromising stability

Hormonal tablets require rapid and reproducible release. Excessive lubricant can create hydrophobic surfaces and delay wetting. Higher compression force can improve mechanical strength but slow disintegration. Coating polymers can affect water penetration if the film is too thick or poorly formulated.

A formulation team should treat dissolution as a multidimensional control problem involving:

• Disintegrant type and level
• Granule porosity
• Compression force
• Lubrication time
• Coating weight
• Tablet hardness
• Storage humidity
• Packaging moisture barrier

The most commercially attractive reformulations are those that improve process capability while maintaining the same active ingredients and dosage regimen.

5. Separate the Fe-tablet strategy from the hormone-tablet strategy

The Fe products have two distinct tablet populations. The ferrous fumarate tablets must be visually and physically distinguishable from the hormonal tablets, while remaining compatible with the blister or wallet pack.

Colorants, coating systems, tablet shape, and embossing can reduce medication errors. The iron tablets should not be so similar to active tablets that a patient could mistake the regimen sequence. Packaging and labeling are part of the excipient and adherence strategy because the product is administered through a calendar-based daily sequence.

What formulation patents protect Junel?

The principal commercial protection for Junel is unlikely to come from a new chemical entity patent. Norethindrone acetate and ethinyl estradiol are long-established active ingredients, and combination oral contraceptives have been marketed for decades. The practical protection profile is therefore different from that of a recently approved small molecule.

Potentially relevant rights can include:

• Formulation patents covering excipient ratios or release characteristics
• Manufacturing patents covering granulation, blending, or coating
• Packaging patents covering calendar packs or dose sequencing
• Method-of-use patents covering contraceptive or noncontraceptive uses
• Trademark and trade-dress rights covering the Junel brand
• Regulatory exclusivity, if any product-specific exclusivity remains

Public product labeling does not establish a current, enforceable patent barrier for every Junel strength or presentation. Patent and Orange Book status must be assessed by product-specific FDA listing, patent number, expiration date, and litigation history. The FDA Orange Book is the controlling source for listed patents and exclusivity associated with approved drug products (FDA, 2024a).

When does Junel lose exclusivity?

Junel is already a mature product category with generic competition. The relevant commercial question is not the expiration of an original Junel compound patent. It is whether a specific branded presentation retains meaningful channel, supply, or formulation differentiation.

Exclusivity category	Junel commercial relevance
New chemical entity exclusivity	Not expected to be relevant because the active ingredients are long established
Original drug patent	Any original rights would generally be expired or commercially immaterial
Formulation patent	Must be confirmed by product-specific patent records
Method-of-use patent	May affect labeled or carved-out uses but is not normally the main barrier for contraceptive substitution
Regulatory exclusivity	Must be confirmed in the current FDA approval record
Trademark protection	Can remain commercially relevant after generic entry
Supply and distribution control	Often more important than patent protection in a mature oral contraceptive market

A generic entrant typically competes through an abbreviated new drug application, using the relevant reference listed drug and demonstrating pharmaceutical equivalence and bioequivalence. A 505(b)(2) pathway may be appropriate for a materially modified formulation, delivery system, or dosing presentation, but it adds clinical and regulatory complexity (FDA, 2024b).

What is the Orange Book status of Junel?

Orange Book analysis should distinguish between:

1. The reference listed drug for the relevant strength and dosage form.
2. Approved abbreviated new drug applications.
3. Listed patents, if any.
4. Pediatric exclusivity or other regulatory exclusivity.
5. Discontinued, withdrawn, or active marketing status.

For a mature contraceptive product, an applicant should not assume that the absence of a prominent patent dispute means that every formulation is unrestricted. The relevant checks include:

• Junel 1/20 versus Junel Fe 1/20
• Junel 1.5/30 versus Junel Fe 1.5/30
• Active versus discontinued presentations
• Product-specific patent listings
• Approved labeling and therapeutic equivalence codes
• Any litigation under the Hatch-Waxman framework

A Paragraph IV certification would be material only if a listed patent remains relevant to the targeted reference product. Where no blocking patent remains, an ANDA applicant may pursue a Paragraph III or Paragraph I certification, depending on the Orange Book record and patent status (FDA, 2024a).

Which companies are challenging Junel or competing with it?

Competition comes from several groups:

Generic oral contraceptive manufacturers

Generic manufacturers compete on price, wholesaler availability, pharmacy substitution, and payer coverage. The competitive set includes products equivalent or similar to norethindrone acetate and ethinyl estradiol tablets, including Fe presentations.

Branded oral contraceptives

Junel competes with branded and authorized-generic versions of other combined oral contraceptives, including products based on:

• Norethindrone and ethinyl estradiol
• Levonorgestrel and ethinyl estradiol
• Norgestimate and ethinyl estradiol
• Drospirenone and ethinyl estradiol
• Desogestrel and ethinyl estradiol

These products differ in estrogen dose, progestin pharmacology, adverse-event profile, packaging, price, and prescriber familiarity.

Long-acting and nonoral contraceptives

Intrauterine systems, implants, injections, patches, and vaginal rings compete for the same contraceptive treatment decision. These products can reduce daily adherence burden but generally have higher acquisition costs and different clinical tradeoffs.

How strong is the Junel patent estate?

The Junel patent estate should be regarded as commercially limited unless a current product-specific formulation or manufacturing patent is identified. The strongest defensible assets are more likely to be:

• Brand recognition
• Pharmacy and payer placement
• Stable supply
• Regulatory history
• Manufacturing know-how
• Packaging execution
• Patient and prescriber familiarity

A formulation patent based only on conventional excipients may face validity and obviousness challenges if it lacks an unexpected technical effect. Stronger patent candidates would require measured advantages such as:

• Improved content uniformity at unusually low active loadings
• Superior dissolution after accelerated stability testing
• Reduced degradation under high humidity
• A distinctive ferrous fumarate tablet architecture
• A non-obvious packaging and dosage-sequencing system
• Manufacturing controls that produce a reproducible clinical or quality benefit

Patentability should be assessed separately from freedom to operate. A new lactose-free formulation may be patentable in narrow circumstances, but it could still practice third-party rights covering excipient combinations, coatings, packaging, or manufacturing processes.

What commercial opportunities exist for Junel excipient reformulation?

Lactose-free or reduced-lactose Junel-equivalent products

This is the clearest formulation-led opportunity. The value proposition is targeted rather than universal: pharmacy benefit channels, telehealth platforms, specialty women’s-health services, and consumers who actively avoid lactose-containing tablets.

The product would need a credible differentiation package:

• Same active ingredients and strength
• Comparable bioavailability
• Smaller or easier-to-swallow tablet
• Clear excipient disclosure
• Competitive unit cost
• Reliable supply across multiple excipient vendors

Premium adherence packaging

Calendar blister packs, day-of-week labeling, color-coded active and Fe tablets, and refill reminders can support adherence. Packaging patents may offer more defensible protection than a conventional tablet formula, but the system must be evaluated for child resistance, moisture protection, dispensing efficiency, and pharmacy workflow.

Authorized-generic supply

A branded manufacturer or licensee can supply an authorized generic under a private-label agreement. This approach monetizes manufacturing capability while limiting brand erosion. The key commercial variables are:

• Transfer price
• Volume commitment
• Exclusivity by channel
• Manufacturing site redundancy
• Product liability allocation
• Recall and pharmacovigilance obligations
• Rights to reformulated versions

Dual-source manufacturing

Because oral contraceptive supply has historically been exposed to manufacturing interruptions, a second qualified manufacturing site can have commercial value even without a patent. A formulation that uses globally available excipients and avoids single-source colorants or specialty coating materials is easier to transfer.

Alternative dosage forms

Chewable, orally disintegrating, or smaller-dose presentations could improve patient convenience. They also create greater regulatory risk because taste masking, dose uniformity, dissolution, and bioequivalence become more complex. A modified presentation may be better suited to a 505(b)(2) strategy than a straightforward ANDA.

Ferrous fumarate-free calendar products

A non-Fe product can reduce manufacturing complexity and eliminate iron-related excipient concerns. Its commercial disadvantage is the loss of the seven-day tablet sequence, which may reduce behavioral adherence for some users. A packaging-based reminder system can partially replace that function.

What generic entry risks exist for Junel?

Generic-entry risk is high in a mature oral contraceptive category. The main risks are:

Risk	Business impact
Pharmacy substitution	Reduces brand retention and increases price pressure
Multiple ANDA approvals	Compresses gross margin
Wholesaler delisting	Reduces availability and prescription capture
Manufacturing interruption	Creates lost sales and reputational damage
Excipient supply disruption	Delays batch release or requires comparability work
Labeling differences	Creates pharmacist or prescriber confusion
Fe-tablet mix-up	Increases medication-error and recall exposure
Formulation change	Can trigger new bioequivalence or stability requirements

A generic launch can occur through an authorized generic, an independent ANDA, or a private-label arrangement. Market entry timing depends on approval status, patent certifications, regulatory review, manufacturing readiness, and commercial contracting rather than on a single Junel patent expiration date.

What litigation and settlement issues affect Junel?

No litigation or settlement should be treated as current without a product-specific review of federal court dockets, FDA records, and company disclosures. For a mature oral contraceptive, the most relevant legal issues are usually:

• ANDA patent litigation under 35 U.S.C. § 271(e)(2)
• Trademark disputes involving brand and generic naming
• Trade-dress claims involving tablet color or packaging
• Product liability claims involving contraceptive risks
• Manufacturing and supply agreements
• Authorized-generic licensing arrangements
• Recall and quality-system disputes

A settlement can affect launch timing, authorized-generic rights, supply territories, and pricing restrictions. It does not necessarily indicate that the underlying formulation patent is strong.

How does Junel compare with competing oral contraceptives?

Attribute	Junel	Levonorgestrel/ethinyl estradiol products	Drospirenone/ethinyl estradiol products
Progestin	Norethindrone acetate	Levonorgestrel	Drospirenone
Typical market position	Low-cost, established generic and branded category	Broad generic availability and long clinical history	More differentiated branded and generic positioning
Excipient opportunity	Lactose-free, low-cost, Fe packaging, supply resilience	Similar cost and packaging opportunities	More emphasis on brand, indication, and formulation differentiation
Patent leverage	Generally limited for mature presentations	Generally limited for mature presentations	Product-specific patents may be more relevant depending on brand
Commercial differentiator	Price, access, familiarity, adherence packaging	Price and contraceptive history	Progestin-specific positioning and branded demand

Junel’s strongest competitive position is usually operational. A manufacturer with stable quality, low cost, dependable distribution, and clear packaging can compete effectively despite limited patent protection.

What is the FDA regulatory pathway for a Junel reformulation?

A conventional generic product generally uses the ANDA pathway. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the relevant reference listed drug, comply with current good manufacturing practice requirements, and match key dosage-form and labeling requirements.

A reformulation may require additional work when it changes:

• Active-to-excipient interaction
• Tablet disintegration or dissolution
• Bioavailability
• Tablet sequence or regimen
• Dosage form
• Route of administration
• Clinical labeling
• Ferrous fumarate content or presentation

A 505(b)(2) application may be more suitable for a new presentation that cannot rely fully on the ANDA framework. The regulatory strategy should be selected before committing to a formulation claim that depends on novel clinical or pharmacokinetic behavior (FDA, 2024b).

What revenue exposure does Junel create?

Revenue exposure is concentrated in volume and price rather than patent duration. The main drivers are:

• Prescription volume
• Net price after rebates
• Generic substitution rate
• Medicaid and commercial payer mix
• Pharmacy benefit manager placement
• Authorized-generic pricing
• Manufacturing cost per tablet pack
• Product availability
• Return and chargeback rates

Because the product is a daily-use contraceptive, a small per-pack cost reduction can have a large effect at scale. Excipients that reduce batch failures, improve compression speed, or permit dual sourcing may create more value than premium excipients with limited patient-facing benefit.

Key Takeaways

• Junel is a mature norethindrone acetate and ethinyl estradiol oral contraceptive franchise.
• The Fe products add ferrous fumarate tablets to preserve the daily dosing routine.
• The highest-value excipient work involves low-dose content uniformity, dissolution control, tablet robustness, and supply reliability.
• Lactose-free formulation, smaller tablets, improved calendar packaging, and dual-source excipient systems are credible commercial opportunities.
• Junel’s commercial protection is more likely to depend on brand, channel access, manufacturing, and packaging than on a blocking compound patent.
• Generic-entry risk is high, so cost, availability, and pharmacy substitution should drive the business case.
• Any patent, Paragraph IV, Orange Book, litigation, or settlement conclusion must be tied to the specific strength, dosage form, manufacturer, and current FDA record.

FAQs

Can Junel tablets be reformulated without changing the active ingredients?

Yes. A manufacturer can change excipients while retaining norethindrone acetate and ethinyl estradiol, but the revised product must meet applicable equivalence, dissolution, stability, manufacturing, and labeling requirements.

Is ferrous fumarate necessary for contraceptive efficacy?

No. Ferrous fumarate is present in the Fe tablets and does not provide contraceptive activity. Its principal product function is to occupy the seven non-hormonal tablet days and maintain the daily dosing sequence.

Is a lactose-free Junel equivalent commercially attractive?

It can be attractive in targeted channels, particularly telehealth, pharmacy services, and patient segments seeking lactose-free products. The value depends on incremental manufacturing cost, claims substantiation, and the ability to maintain bioequivalence.

Can Junel packaging be patented?

A conventional blister pack is difficult to protect broadly. A technically specific system involving dose sequencing, error reduction, child resistance, moisture control, or dispensing integration may support narrower patent claims if it satisfies novelty and non-obviousness requirements.

Would an orally disintegrating Junel product use an ANDA?

The pathway depends on how closely the proposed product matches the reference listed drug. A materially different dosage form, absorption profile, or administration method may require a 505(b)(2) application rather than a conventional ANDA.

References

1. DailyMed. (2024a). Junel Fe 1/20: Norethindrone acetate and ethinyl estradiol tablets, ferrous fumarate tablets prescribing information. U.S. National Library of Medicine.

2. DailyMed. (2024b). Junel Fe 1.5/30: Norethindrone acetate and ethinyl estradiol tablets, ferrous fumarate tablets prescribing information. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2024b). Abbreviated new drug application submissions: Refuse-to-receive standards. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2024c). Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA: Guidance for industry. Center for Drug Evaluation and Research.